New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
04:55 EDTATOS, ATOS, RHHBY, RHHBY, SQNM, SQNM, GHDX, GHDX, SAP, SAP, AET, AET, IBM, IBM, UNH, UNHPMWC, Inc to host a conference
Personalized Medicine World Conference is being held in Mountain View, California on January 28-29.
News For ATOS;RHHBY;SQNM;GHDX;SAP;AET;IBM;UNH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 15, 2015
16:32 EDTIBMBerkshire Hathaway gives quarterly update on stakes
NEW STAKES: None. INCREASED STAKES: IBM (IBM), Precision Castparts (PCP), Wells Fargo (WFC), Phillips 66 (PSX), and US Bancorp (USB). DECREASED STAKES: National Oilwell Varco (NOV), Viacom (VIAB), Bank of New York Mellon (BK), MasterCard (MA), and Visa (V). LIQUIDATED STAKES: None.
11:02 EDTGHDXGenomic Health says Oncotype DX shown to lower overall healthcare costs
Genomic Health announced results from three studies that show the real-world positive impact of the Oncotype DX Genomic Prostate Score and the test's value in managing healthcare costs associated with treatment decisions in low-risk patients. An analysis of the performance of the Oncotype DX GPS in the first 4,000 men tested showed that the test refined patient risk for one in four men across all groups of patients, the company said. In a separate study, researchers analyzed the clinical and economic implications of adding GPS to risk assessment compared to clinical and pathological assessment alone in the management of clinically low-risk prostate cancer. Results showed incorporating GPS into prostate cancer management resulted in a cost reduction of approximately $2,000 per patient in the first three years after diagnosis.
08:31 EDTGHDXGenomic Health announces results from studies of Oncotype DX GPS
Genomic Health announced results from three studies that show the real-world positive impact of the Oncotype DX Genomic Prostate Score and the test's value in managing healthcare costs associated with treatment decisions in low-risk patients. An analysis of the performance of the Oncotype DX GPS in the first 4,000 men tested showed that the test refined patient risk for one in four men across all groups of patients. In a separate study, researchers analyzed Oncotype DX test results from 200 U.S. prostate cancer patients to see how the change in their treatment decision based on the GPS results affected the cost of their treatment. Results showed that immediate treatment costs declined by more than $5,700 per patient. This reduction in costs was associated with increased use of active surveillance from 44 percent to 70 percent of the time. These results indicate that incorporating GPS into treatment decisions can reduce overall healthcare costs within five years. Genomic Health researchers analyzed data compiled from four different Oncotype DX prostate cancer test studies involving 138 African-American patients. Results of this analysis showed that the tumor biology measured by the Oncotype DX GPS was similar between African-American and Caucasian men, reinforcing findings from the second validation study conducted in collaboration with the Uniformed Services University of the Health Sciences' Center for Prostate Disease Research.
May 14, 2015
09:22 EDTRHHBYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:33 EDTUNHUnitedHealth would consider Optum spinoff if benefits erode, says UBS
Subscribe for More Information
May 13, 2015
18:12 EDTRHHBYGenentech alectinib shrank tumors in about half of ALK-positive NSCLC patients
Subscribe for More Information
17:04 EDTRHHBYGenentech announces interim results from POPLAR study
Genentech, a member of the Roche Group announced interim results from a global, randomized Phase II study, POPLAR, in people with previously treated non-small cell lung cancer, NSCLC. The study showed the investigational cancer immunotherapy MPDL3280A doubled the likelihood of survival; hazard ratio [HR]=0.47) in people whose cancer expressed the highest levels of PD-L1 compared with docetaxel chemotherapy. An improvement in survival was also observed in people who had medium and high or any level of PD-L1 expression, as characterized by a test being developed by Roche. MPDL3280A was generally well tolerated and adverse events were consistent with what has been previously reported for MPDL3280A in NSCLC. Updated results will be presented in an oral session at the 51st Annual Meeting of the American Society of Clinical Oncology. “In our study of MPDL3280A in previously treated lung cancer, the amount of PD-L1 expressed by a person’s cancer correlated with improvement in survival,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “The goal of PD-L1 as a biomarker is to identify people most likely to experience improved overall survival with MPDL3280A alone, and which people may be appropriate candidates for a combination of medicines.”
10:18 EDTAETAnalyst says sell Humana amid 'wishful' takeover speculation
Subscribe for More Information
09:03 EDTIBMIBM partners with Teleflora for large florists network
Subscribe for More Information
May 12, 2015
13:03 EDTAETAetna repeats view of FY15 operating EPS $7.20-$7.40, consensus $7.38
Subscribe for More Information
11:53 EDTAETAnalyst predicts large transaction 'imminent' for Aetna
Subscribe for More Information
10:04 EDTAETHigh option volume stocks
Subscribe for More Information
09:53 EDTAETAetna merger with Cigna or Humana likely 'imminent,' says Leerink
Subscribe for More Information
May 11, 2015
18:29 EDTGHDXAffordable Care Act guidance says insurers must cover BRCA1, BRCA2 testing
The United States Department of Labor issued updated Affordable Care Act guidance, which mandates that health insurers must cover testing for breast and ovarian cancer through analysis of the BRCA1 and BRCA2 genes. Myriad (MYGN), Foundation Medicine (FMI), and Genomic Health (GHDX) compete in the genetic testing space. Reference Link
15:06 EDTAETAetna backs FY15 operating EPS $7.20-$7.40, consensus $7.38
In a regulatory filing earlier, Aetna reported that during upcoming investor meetings in May, the company expects to reaffirm its FY15 operating EPS guidance of $7.20-$7.40. Current FY15 EPS consensus is $7.38.
07:40 EDTUNHFocus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertex’s Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasn’t announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link
07:13 EDTUNHUnitedHealth management to meet with UBS
Subscribe for More Information
06:51 EDTAETAetna management to meet with Leerink
Meeting to be held in Hartford, CT on May 11 hosted by Leerink.
05:11 EDTRHHBYRoche receives FDA approval for cobas KRAS Mutation Test
Roche announced that the FDA has approved the cobas KRAS Mutation Test for diagnostic use. The real-time PCR test is designed to identify KRAS mutations in tumor samples from metastatic colorectal cancer, or mCRC, patients and aid clinicians in determining a therapeutic path for them.
May 8, 2015
09:12 EDTIBMIBM partnes with Ionic for mobile app development
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use